kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
1,995.0
JPY
-5.0
(-0.25%)
Dec 5, 11:30 am JST
12.86
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
1,993.9
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
19.8
PBR
2.22
Yield
3.91%
Margin Trading Ratio
30.74
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
1,999.5 JPY 12.88 USD
Previous Close Dec 4
2,000.0 JPY 12.87 USD
High Dec 5, 9:00 am
2,009.0 JPY 12.95 USD
Low Dec 5, 9:07 am
1,967.5 JPY 12.67 USD
Volume
3,744,700
Trading Value
7.46B JPY 0.05B USD
VWAP
1991.9 JPY 12.85 USD
Minimum Trading Value
199,500 JPY 1,286 USD
Market Cap
3.61T JPY 0.02T USD
Number of Trades
3,921
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
6,032
1-Year High Feb 12, 2025
24,753
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 631,500 1,329,800 2.11
Nov 21, 2025 709,900 1,310,500 1.85
Nov 14, 2025 740,200 1,693,100 2.29
Nov 7, 2025 733,700 2,213,900 3.02
Oct 31, 2025 566,100 3,056,300 5.40
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.